MPP-L and CMP-L are phenotypically defined as CD34+ AML, positive for myeloid markers (CD13+CD33+CD117+); and differ by their expression of cytoplasmic MPO (<10% for MPP-L and within the range of 10–70% for CMP-L). This evidence concerns the gene CD34 and acute myeloid leukemia.